Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Zymeworks and Merck have forged research partnership to advance Zymeworks’ proprietary Azymetric platform for bi-specific antibody therapeutic candidates' development.
Subscribe to our email newsletter
As per the agreement Zymeworks has granted Merck, through a subsidiary, a worldwide license to develop and commercialize bi-specific antibodies toward certain exclusive therapeutic targets.
Zymeworks will receive an upfront fee, R&D and regulatory milestones with a potential value of up to $187m, as well as tiered royalty payments on sales of products.
Merck will have exclusive worldwide commercialization rights to products derived from the collaboration.